NeuroSense Therapeutics
improved respiratory function decline attenuated disease progression phase a month data intermediate formulation therapeutics by by | NeuroSense Therapeutics
Company
Deck Type
Sector
Industry
Deck date
June 2023
Slide
15 of 34
Related slides by other companies
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase | RenovoRx
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase | RenovoRx
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase median overall survival gem alone | RenovoRx
ATAI
Investor Presentation
March 2023
phase proof of concept trial design all subjects tid tid placebo trial status in data anticipated randomized week study of and patients with | ATAI
Other recent decks by NeuroSense Therapeutics
See all presentations (4 decks)
Investor Presentation
October 2024
Investor Presentation
January 2024
Investor Presentation
December 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights